Corventis out of San Jose, CA won FDA 510(k) approval to market the NUVANT Mobile Cardiac Telemetry (MCT) System. The company’s wireless technology revolves around the chest worn PiiX electrocardiograph, a high precision single lead ECG, which sends readings to a mobile phone based device for further transmission of the data to a hosted application for clinician’s access.
The NUVANT Mobile Cardiac Telemetry System is the second product launched from the Corventis portfolio of wireless cardiovascular solutions. Designed with a specific focus on ambulatory arrhythmia monitoring, the NUVANT MCT System leverages the low profile form factor, advanced algorithms and multi-sensor capabilities of the PiiX wearable platform to enable continuous monitoring for a broad set of arrhythmias, including atrial fibrillation, as well as patient falls that may be associated with arrhythmias. Patients can also trigger the collection of an electrocardiogram (ECG), on-demand, upon experiencing symptoms, further aiding in the correlation of symptoms with the ECG.
All ECGs are promptly transmitted to the Corventis Monitoring Center via the wireless-enabled zLink, for review and response by trained cardiographic technicians. Physicians receive prompt notification of urgent events as well as actionable information in the form of Episode Reports, Daily Reports and End of Use Reports via fax, email and/or the secure www.corventis.com website. Using this information, a physician can diagnose symptomatic and asymptomatic cardiac arrhythmias and proactively manage patients remotely from anywhere across the globe.
Press release: CORVENTIS ANNOUNCES FDA CLEARANCE AND US LAUNCH OF THE NUVANT™ MOBILE CARDIAC TELEMETRY SYSTEM…
Product page: NUVANT™ Mobile Cardiac Telemetry (MCT) System
Flashbacks: Piix Wireless Home Cardiac Monitoring to Undergo Randomized Trial; PiiX Monitors for Signs of Decompensated Heart Failure